Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clobazam - Lundbeck

Drug Profile

Clobazam - Lundbeck

Alternative Names: Frisium; Onfi; Urbanol

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OVATION Pharmaceuticals
  • Developer Lundbeck Inc
  • Class Antiepileptic drugs; Anxiolytics; Benzodiazepines
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Lennox-Gastaut syndrome
  • Phase III Epilepsy
  • No development reported Dravet syndrome

Most Recent Events

  • 04 Sep 2018 No development reported - Phase-III for Dravet syndrome (Adjunctive treatment, In adolescents, In children, In infants) in Mexico, USA (PO)
  • 03 May 2018 Lundbeck LLC terminates a phase III trial due to recruitment issues in Epilepsy in USA (PO) (NCT02134366)
  • 12 Oct 2015 No recent reports on development identified - Phase-III for Lennox-Gastaut syndrome (Adjunctive treatment, In children, In adults) in Australia, Belarus, Lithuania and India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top